The Usefulness of Xuefu Zhuyu Tang for Patients with Angina Pectoris: A Meta-Analysis and Systematic Review

Table 1

Characteristics of the included studies.

Study ID	AP subtypes	Criteria	Participants included; (experimental/control)	Percent of male (%)	Mean age (years)	Interventional		Duration (weeks)	Outcome measures
						Experimental	Control
Li, 2008 [21]	SAP	ISFC/WHO	40/40	67.5	63.5	XFZYT + TAMs	TAMs	4	RAS
Wang, 2011 [28]	SAP	ISFC/WHO	20/20	57.5	60.6	XFZYT + TAMs	TAMs	8	RAS, ECG, and AEs
Zhao, 2009 [26]	SAP	ISFC/WHO	30/30	45.0	58.8	XFZYT + TAMs	TAMs	4	RAS and ECG
Yang, 2010 [18]	SAP	ISFC/WHO	50/50	56.0	48.5	XFZYT + TAMs	TAMs	4	RAS, ECG, and HDL-C
Chu et al., 2009 [23]	UAP	ACCF/AHA	30/30	63.3	60.3	XFZYT + TAMs	TAMs + placebo	4	QL and AEs
Zheng and Wang, 2009 [24]	UAP	ISFC/WHO	30/30	66.7	65	XFZYT + TAMs	TAMs	8	ECG, RNU, and AEs
Lv, 2009 [22]	Both	CSC	32/30	69.4	60.9	XFZYT + TAMs	TAMs	4	RAS and ECG
Wang et al., 2000 [20]	Both	ISFC/WHO	34/27	66.7	58	XFZYT + TAMs	TAMs	4	RAS, ECG, and AEs
Du et al., 2013 [29]	Both	ISFC/WHO	92/50	62.7	65	XFZYT + TAMs	TAMs	6	RAS, HDL-C, and AEs
Wang and Jing, 2007 [19]	Both	ISFC/WHO	31/30	52.5	62.5	XFZYT + TAMs	TAMs + placebo	4	RAS, RNU, and AEs
Li and Zhang, 2011 [27]	Both	ISFC/WHO	60/60	72.5	56.3	XFZYT + TAMs	TAMs	4	RAS and ECG
Liu et al., 2007 [25]	Both	CSC	45/45	NA	NA	XFZYT + TAMs	TAMs	8	RAS and AEs
Zhang, 2012 [17]	Both	CSC	50/50	49	69.9	XFZYT + TAMs	TAMs	4	RAS, ECG, HDL-C, and AEs
Li, 2009 [30]	Both	ISFC/WHO	40/40	53.8	64.5	XFZYT + TAMs	TAMs	4	RAS, ECG, and AEs

SAP: stable angina pectoris; UAP: unstable angina pectoris; NA: not available; XFZYT: Xuefu Zhuyu Tang; TAMs: traditional antianginal medications; RAS: relief of anginal symptoms; ECG: electrocardiogram; RNU: reduction of nitroglycerin use; AEs: adverse effects; QL: quality of life; HDL-C: high-density lipoprotein cholesterol.